Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10703MR)

This product GTTS-WQ10703MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10703MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8505MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ9898MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ15255MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ15885MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ9575MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ9732MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ6726MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ3324MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW